Psoriasis im JDDG

Background and objectives Mycosis fungoides (MF) accounts for the majority of cutaneous lymphomas (CL). There is a documented delay in the diagnosis of early-stage MF. However, its timely diagnosis is paramount to avoid potentially harmful therapies and undue patient distress. The aim of this study was to examine and compare the views held by both specialists and non-specialists in CL regarding the diagnosis of early-stage MF, to identify clinical needs.Methods Two distinct questionnaires were d

Used since 2011 in the USA and 2012 in the EU, Janus kinase inhibitors (JAKi) are gaining increasing acceptance as a treatment for dermatological diseases such as atopic dermatitis, psoriasis, psoriatic arthritis, alopecia areata, chronic hand eczema and vitiligo. Knowledge of their mechanism of action and potential side effects is necessary for a safe and effective use. Their short half-life requires daily administration, enables good controllability and is appreciated by many patients due to t

No abstract supplied.Weiterlesen

Background There are only limited histomorphological data on the response of psoriatic skin lesions to topical dithranol. In vivo reflectance confocal microscopy (RCM) in psoriatic skin is highly correlated with histopathological findings and allows non-invasive monitoring of treatment effects on a cellular level.Patients and methods Prospective, single-center pilot study at a university-based clinic of dermatology between January 1st and August 30th, 2016. Psoriatic lesions of 20 patients recei

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Background The pathogenesis of nummular eczema (NE) remains unclear, and no targeted therapy has been approved. Apremilast is a small molecule inhibitor targeting phosphodiesterase-4.Patients and methods A phase IIb randomized, double-blind, placebo-controlled study evaluating the effects of apremilast or placebo in patients with NE. Patients received apremilast (30 mg BID) or placebo until week 16 followed by an open label phase in which all patients were treated with apremilast until week 32.

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Background and objectives Continuous biologic treatment is recommended for patients with psoriasis; however, treatment interruption in daily practice is inevitable. The impact of treatment interruption is difficult to study in a real-world setting. In Taiwan, biologics are reimbursed by the National Health Insurance for moderate-to-severe psoriasis for a 2-year course, followed by regulatory discontinuation. Thus, our study provides pragmatic data on the impact of the interruption of biologics t

No abstract supplied.Weiterlesen

Gluten-related disorders (GRDs) encompass a spectrum of clinical manifestations triggered by gluten ingestion in genetically susceptible individuals. These disorders include celiac disease (CD) and non-celiac gluten sensitivity (NCGS) and present with both intestinal and extraintestinal symptoms, including skin manifestations. Besides the well-known association between CD and dermatitis herpetiformis, considered as the cutaneous manifestation of CD, other dermatoses have been associated to GRDs.

No abstract supplied.Weiterlesen

Tuberculosis (TB) continues to be a leading cause of death in many countries, and also remains a significant concern in Germany, particularly due to migration. The diagnosis of rare cutaneous tuberculosis is challenging as it manifests in various clinical forms that resemble more common dermatological conditions. Especially in paucibacillary forms, gold-standard diagnostic tests may yield negative results, complicating the identification of the disease. Therefore, a strong clinical suspicion bas

No abstract supplied.Weiterlesen

Background and objectives Knowledge on patient care gaps of prurigo nodularis (PN) is limited. This retrospective chart review (ADVANCE PN) investigated unmet medical needs and gaps in diagnostics, treatment, and management of patients with PN in routine care in Germany.Patients and methods Medical records for adults newly diagnosed with PN between January 2012 and December 2022 from dermatologic clinics and office-based dermatologists were analyzed. Baseline demographics, treatment patterns, di

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Background and objectives Flexible biologic therapy dosing regimens in psoriasis management are common, but data from routine care in Germany are scarce. This study evaluated treatment adjustments for biologic therapies commonly prescribed in Germany.Patients and methods Charts for up to 100 consecutive patients treated at 29 centers were reviewed. Data were extracted for adults (aged 18-65 years) with moderate-to-severe plaque psoriasis treated with adalimumab, guselkumab, ixekizumab, secukinum

Background and objective Erosions of the skin and mucous membranes with epidermal dysmaturation are a known side effect of cytostatic chemotherapy regimens and can also be observed during low-dose methotrexate (MTX) therapy. The study aimed to delineate the clinical and histopathological alterations.Patients and methods A database search of the archive for dermatopathology was conducted, identifying 22 patients who developed epidermal dysmaturation on low-dose MTX. Clinical and laboratory change

Objective To construct a predictive model for Psoriatic Arthritis (PsA) based on clinical and ultrasonic characteristics in patients with plaque psoriasis (PsP).Patients and methods Demographic, clinical, and ultrasound data were collected from patients with PsP and PsA between May 2019 and December 2022.Results A total of 212 patients with PsP and 123 with PsA in the training cohort, whereas the validation cohort comprised 91 patients with PsP and 49 with PsA. The multivariate logistic regressi